Oculis to Participate in Upcoming Investor Conferences
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq:…
Oculis Publishes 2025 Consolidated Financial Statements
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press…
Press Release: Sanofis Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director …
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®)…
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presented positive updated data from the ALLOHA™ Phase 1 heme trial at…
Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
Company to Host Conference Call at 8:30am ET March 04, 2026 07:00…
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”),…
Inteleos 2026 Leadership Elections Accelerate Vision for Global Healthcare
ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Inteleos today announced its…
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
